Market Place
Sourcing Support
Vertex buys ViaCyte for $320M, clearing out T1D competition
12 Jul 2022 //
FIERCEBIOTECH
‘Disappointing’ ViaCyte data risks future of company’s attempted diabetes cure
23 Dec 2021 //
ENDPTS
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy
17 Nov 2021 //
ENDPTS
CRISPR Therapeutics and ViaCyte to Start Trial of the First Gene-Edited Cell
16 Nov 2021 //
GLOBENEWSWIRE
ViaCyte staffs up CSO role to drive diabetes treatments
13 Sep 2021 //
FIERCEBIOTECH
ViaCyte shows off first proof-of-concept for diabetes stem cell transplants
29 Jun 2021 //
ENDPTS
ViaCyte shows off first proof-of-concept for diabetes stem cell transplants
28 Jun 2021 //
ENDPTS
After years of failure, ViaCyte shows off first proof-of-concept for diabetes
26 Jun 2021 //
ENDPTS
ViaCyte scores $45M for type 1 diabetes drugs in midstage trials
10 Jun 2021 //
FIERCEBIOTECH
ViaCyte scores $45M for type 1 diabetes drugs in midstage trials
09 Jun 2021 //
FIERCEBIOTECH
ViaCyte Announces Initiation of Ph 2 Study of Cell Therapy for Type 1
03 Feb 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.